Posted by Michael Wonder on 04 Aug 2021
MHRA approves first immunotherapy treatment for mesothelioma
3 August 2021 - The MHRA has approved the combination of nivolumab plus ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma in Great Britain.
Bristol Myers Squibb’s immunotherapy combination is the first treatment option approved for patients in the UK for more than 15 years.
